Merck to acquire Idenix for $3.85bn

12-06-2014

Merck to acquire Idenix for $3.85bn

Photo: 360b / Shutterstock.com

Drug giant Merck is to acquire biopharmaceutical company Idenix for $24.50 per share, valuing the purchase at around $3.85 billion.


Merck; Idenix; merger and acquisition; hepatitis C

LSIPR